IP Library Patent Application 12433082
Patent Application
App. No. 12/433,082

DUAL DRUG STENT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/433,082
Abstract

Implantable medical devices may be utilized to locally delivery one or more drugs or therapeutic agents to treat a wide variety of conditions, including the treatment of the biological organism's reaction to the introduction of the implantable medical device. These therapeutic agents may be released under controlled and directional conditions so that the one or more therapeutic agents reach the correct target area, for example, the surrounding tissue and/or the bloodstream.

Claims (10)

1 . A drug delivery device comprising:

an implantable intraluminal scaffold having a luminal surface and an abluminal surface;

a plurality of openings in the intraluminal scaffold;

a first portion of the plurality of openings comprising an mTOR inhibitor composition and a base structure configured to allow the mTOR inhibitor in the mTOR inhibitor composition to elute substantially in the abluminal direction; and

a second portion of the plurality of openings comprising a phosphodiesterase III inhibitor composition and at least one of a cap or a base structure configured to allow the phosphodiesterase III inhibitor in the phosphodiesterase III inhibitor composition to elute substantially in at least one of the luminal direction or the abluminal direction.

2 . The drug delivery device according to claim 1 , wherein the mTOR inhibitor composition comprises a rapamycin composition.

3 . The drug delivery device according to claim 2 , wherein the rapamycin composition comprises a sirolimus composition.

4 . The drug delivery device according to claim 1 , wherein the phosphodiesterase III inhibitor composition comprises cilostazol.

5 . The drug delivery device according to claim 1 , wherein the phosphodiesterase III inhibitor composition comprises at least one of milrinone, vesnarionone, enoximone, pimobendan and meribendan.

6 . The drug delivery device according to claim 1 , wherein the implantable intraluminal scaffold comprises a stent.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2025
From: CARDINAL HEALTH SWITZERLAND 515 GMBH; CARDINAL HEALTH 529, LLC; CORDIS CORPORATION; FLEXIBLE STENTING SOLUTIONS, INC
To: CORDIS US CORP
Reel/Frame 072987/0675 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2017
From: CORDIS CORPORATION
To: CARDINAL HEALTH SWITZERLAND 515 GMBH
Reel/Frame 042126/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2009
From: DAVE, VIPUL BHUPENDRA; FALOTICO, ROBERT; LI, CHENGXUE; NGUYEN, THAI; PARKER, THEODORE L.; ZHAO, JONATHON Z.
To: CORDIS CORPORATION
Reel/Frame 022636/0333 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2009
From: DAVE, VIPUL BHUPENDRA; FALOTICO, ROBERT; LI, CHENGXUE; NGUYEN, THAI; PARKER, THEODORE L.; ZHAO, JONATHON Z.
To: CORDIS CORPORATION
Reel/Frame 022636/0470 →